Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Receivables (2019 - 2025)

aTYR PHARMA's Change in Receivables history spans 7 years, with the latest figure at -$169000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 77.89% year-over-year to -$169000.0; the TTM value through Dec 2025 reached -$863000.0, down 114.68%, while the annual FY2025 figure was -$863000.0, 114.68% down from the prior year.
  • Change in Receivables reached -$169000.0 in Q4 2025 per ATYR's latest filing, down from $544000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $12.0 million in Q4 2022 to a low of -$9.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is $0.0, with a median of -$56000.0 recorded in 2024.
  • Peak YoY movement for Change in Receivables: soared 3819.28% in 2022, then tumbled 109711.11% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $306000.0 in 2021, then skyrocketed by 3819.28% to $12.0 million in 2022, then plummeted by 96.18% to $458000.0 in 2023, then tumbled by 120.74% to -$95000.0 in 2024, then tumbled by 77.89% to -$169000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Change in Receivables are -$169000.0 (Q4 2025), $544000.0 (Q3 2025), and -$490000.0 (Q2 2025).